Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III Study of RO7790121 in Moderately to Severely Active Ulcerative Colitis
jRCT2041240200Phase 3Active, not recruiting
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Apr 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial in autoimmune colitis comparing RO7790121 arm with Placebo arm (2 arms). Started Apr 2025; status: active, not recruiting.
02
Drugs
afimkibart
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on jRCT2041240200.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041240200.